Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial

Diabetic kidney disease (DKD) is the leading cause of ESRD. We conducted an open-label, prospective, randomized trial to determine whether pentoxifylline (PTF), which reduces albuminuria, in addition to renin-angiotensin system (RAS) blockade, can slow progression of renal disease in patients with t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Society of Nephrology 2015-01, Vol.26 (1), p.220-229
Main Authors: Navarro-González, Juan F, Mora-Fernández, Carmen, Muros de Fuentes, Mercedes, Chahin, Jesús, Méndez, María L, Gallego, Eduardo, Macía, Manuel, del Castillo, Nieves, Rivero, Antonio, Getino, María A, García, Patricia, Jarque, Ana, García, Javier
Format: Article
Language:English
Subjects:
Aged
Albumins - analysis
Clinical Research
Diabetes Mellitus, Type 2 - complications
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - urine
Disease Progression
Female
Glomerular Filtration Rate
Humans
Inflammation
Kidney - drug effects
Male
Middle Aged
Pentoxifylline - therapeutic use
Prospective Studies
Research Design
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic kidney disease (DKD) is the leading cause of ESRD. We conducted an open-label, prospective, randomized trial to determine whether pentoxifylline (PTF), which reduces albuminuria, in addition to renin-angiotensin system (RAS) blockade, can slow progression of renal disease in patients with type 2 diabetes and stages 3-4 CKD. Participants were assigned to receive PTF (1200 mg/d) (n=82) or to a control group (n=87) for 2 years. All patients received similar doses of RAS inhibitors. At study end, eGFR had decreased by a mean±SEM of 2.1±0.4 ml/min per 1.73 m(2) in the PTF group compared with 6.5±0.4 ml/min per 1.73 m(2) in the control group, with a between-group difference of 4.3 ml/min per 1.73 m(2) (95% confidence interval [95% CI], 3.1 to 5.5 ml/min per 1.73 m(2); P
ISSN:1046-6673
1533-3450
DOI:10.1681/ASN.2014010012